

# Partha Basu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7240344/publications.pdf>

Version: 2024-02-01

103  
papers

2,518  
citations

201385

27  
h-index

243296

44  
g-index

105  
all docs

105  
docs citations

105  
times ranked

2989  
citing authors

#	ARTICLE	IF	CITATIONS
1	Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. <i>International Journal of Cancer</i> , 2018, 142, 44-56.	2.3	169
2	Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. <i>Vaccine</i> , 2018, 36, 4783-4791.	1.7	117
3	Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. <i>Cut</i> , 2019, 68, 1232-1244.	6.1	113
4	Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in India. <i>International Journal of Cancer</i> , 2004, 112, 341-347.	2.3	107
5	Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1518-1529.	5.1	103
6	Recommendations for screening and early detection of common cancers in India. <i>Lancet Oncology</i> , The, 2015, 16, e352-e361.	5.1	89
7	Women's perceptions and social barriers determine compliance to cervical screening: Results from a population based study in India. <i>Cancer Detection and Prevention</i> , 2006, 30, 369-374.	2.1	79
8	Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. <i>Lancet Oncology</i> , The, 2019, 20, e637-e644.	5.1	76
9	Secondary prevention of cervical cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 73-85.	1.4	62
10	Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. <i>Vaccine</i> , 2020, 38, 1302-1314.	1.7	61
11	Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 175-184.	5.1	55
12	Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India. <i>International Journal of Cancer</i> , 2015, 137, 859-867.	2.3	53
13	Clearance of Cervical Human Papillomavirus Infection by Topical Application of Curcumin and Curcumin Containing Polyherbal Cream: A Phase II Randomized Controlled Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5753-5759.	0.5	53
14	Evaluation of the National Cervical Cancer Screening Programme of Bangladesh and the formulation of quality assurance guidelines. <i>Journal of Family Planning and Reproductive Health Care</i> , 2010, 36, 131-134.	0.9	52
15	The European response to the WHO call to eliminate cervical cancer as a public health problem. <i>International Journal of Cancer</i> , 2021, 148, 277-284.	2.3	52
16	Scaling up proven innovative cervical cancer screening strategies: Challenges and opportunities in implementation at the population level in low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 63-68.	1.0	47
17	Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 26-32.	1.0	45
18	Association between high risk human papillomavirus infection and co-infection with <i>Candida</i> spp. and <i>Trichomonas vaginalis</i> in women with cervical premalignant and malignant lesions. <i>Journal of Clinical Virology</i> , 2017, 87, 43-48.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programs in selected low- and middle-income countries: Study from the IARC COVID-19 impact study group. <i>International Journal of Cancer</i> , 2021, 149, 97-107.	2.3	42
20	Management of cervical premalignant lesions. <i>Current Problems in Cancer</i> , 2018, 42, 129-136.	1.0	39
21	Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline? A population-based cohort study. <i>International Journal of Cancer</i> , 2017, 140, 1850-1859.	2.3	38
22	Study of accuracy of colposcopy in VIA and HPV detection-based cervical cancer screening program. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2014, 54, 570-575.	0.4	37
23	A pilot study to evaluate home-based screening for the common non-communicable diseases by a dedicated cadre of community health workers in a rural setting in India. <i>BMC Public Health</i> , 2019, 19, 14.	1.2	37
24	Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation. <i>JCO Global Oncology</i> , 2021, 7, 416-424.	0.8	34
25	Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2009, 10, 27-34.	0.5	34
26	Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs. <i>South Asian Journal of Cancer</i> , 2013, 02, 187-192.	0.2	33
27	Cancer screening and early diagnosis in low and middle income countries. <i>Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz</i> , 2018, 61, 1505-1512.	7.2	31
28	MassARRAY Spectrometry Is More Sensitive than PreTect HPV-Proofer and Consensus PCR for Type-Specific Detection of High-Risk Oncogenic Human Papillomavirus Genotypes in Cervical Cancer. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3537-3544.	1.8	28
29	Knowledge, Attitude and Practices of Women in Maldives Related to the Risk Factors, Prevention and Early Detection of Cervical Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6691-6695.	0.5	27
30	Acceptability of human papillomavirus vaccine among the urban, affluent and educated parents of young girls residing in Kolkata, Eastern India. <i>Journal of Obstetrics and Gynaecology Research</i> , 2011, 37, 393-401.	0.6	26
31	Tackling cervical cancer in Europe amidst the COVID-19 pandemic. <i>Lancet Public Health</i> , The, 2020, 5, e425.	4.7	26
32	Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in colposcopy and treat approach: A population-based study in rural China. <i>International Journal of Cancer</i> , 2020, 147, 1275-1285.	2.3	26
33	Less than 3 doses of the HPV vaccine – Review of efficacy against virological and disease end points. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1394-1402.	1.4	25
34	Risk-Based Selection of Individuals for Oral Cancer Screening. <i>Journal of Clinical Oncology</i> , 2021, 39, 663-674.	0.8	24
35	Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance. <i>International Journal of Cancer</i> , 2018, 143, 3273-3280.	2.3	23
36	Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 7, 75-81.	4.5	23

#	ARTICLE	IF	CITATIONS
37	Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 589-597.	1.1	22
38	Leveraging vertical COVID-19 investments to improve monitoring of cancer screening programme – A case study from Bangladesh. <i>Preventive Medicine</i> , 2021, 151, 106624.	1.6	22
39	Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 163-171.	4.5	21
40	Thyroid Cancer Incidence in India Between 2006 and 2014 and Impact of Overdiagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2507-2514.	1.8	21
41	Evaluation of a compact, rechargeable, magnifying device to triage VIA and HPV positive women in a cervical cancer screening program in rural India. <i>Cancer Causes and Control</i> , 2016, 27, 1253-1259.	0.8	20
42	Current global status & impact of human papillomavirus vaccination: Implications for India. <i>Indian Journal of Medical Research</i> , 2016, 144, 169.	0.4	19
43	Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 40-47.	1.0	18
44	Eliminating cervical cancer in the COVID-19 era. <i>Nature Cancer</i> , 2021, 2, 133-134.	5.7	18
45	Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. <i>Cancer Letters</i> , 2022, 525, 22-32.	3.2	18
46	Targeted therapy for gynecologic cancers: Toward the era of precision medicine. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 131-136.	1.0	17
47	Prevalence of high-risk human papillomavirus and cervical intraepithelial neoplasias in a previously unscreened population – A pooled analysis from three studies. <i>International Journal of Cancer</i> , 2013, 132, 1693-1699.	2.3	16
48	Physical and methylation status of human papillomavirus 16 in asymptomatic cervical infections changes with malignant transformation. <i>Journal of Clinical Pathology</i> , 2015, 68, 206-211.	1.0	16
49	Invitation strategies and coverage in the population-based cancer screening programmes in the European Union. <i>European Journal of Cancer Prevention</i> , 2019, 28, 131-140.	0.6	16
50	Reproducibility of cervical intraepithelial neoplasia diagnosis on histological review of cervical punch biopsies from a visual inspection with acetic acid and HPV detection-based screening program. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 126, 227-231.	1.0	15
51	Phase 2 Randomized Controlled Trial of Radiation Therapy Plus Concurrent Interferon-Alpha and Retinoic Acid Versus Cisplatin for Stage III Cervical Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 102-110.	0.4	15
52	Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. <i>International Journal of Cancer</i> , 2021, 148, 1419-1427.	2.3	15
53	Using Implementation Science to Advance Cancer Prevention in India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3639-3644.	0.5	15
54	Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. <i>Journal of Medical Virology</i> , 2016, 88, 1271-1278.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Downstaging in opportunistic breast cancer screening in Brazil: a temporal trend analysis. <i>BMC Cancer</i> , 2019, 19, 432.	1.1	14
56	Study of Knowledge, Attitudes, and Practices Toward Risk Factors and Early Detection of Noncommunicable Diseases Among Rural Women in India. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	14
57	HPV detection-based cervical cancer screening program in low-resource setting: lessons learnt from a community-based demonstration project in India. <i>Cancer Causes and Control</i> , 2016, 27, 351-358.	0.8	13
58	Implications of semi-quantitative HPV viral load estimation by Hybrid capture 2 in colposcopy practice. <i>Journal of Medical Screening</i> , 2016, 23, 104-110.	1.1	12
59	Level of human development is associated with cervical cancer stage at diagnosis. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 86-90.	0.4	12
60	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. <i>Vaccine</i> , 2020, 38, 5997-6006.	1.7	11
61	Feasibility, Acceptability, and Efficacy of a Community Health Worker-Driven Approach to Screen Hard-to-Reach Periurban Women Using Self-Sampled HPV Detection Test in India. <i>JCO Global Oncology</i> , 2020, 6, 658-666.	0.8	11
62	Acting on the call: A framework for action for rapid acceleration of access to the HPV vaccination in low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 32-39.	1.0	11
63	Cervical cancer screening & HPV vaccination: a comprehensive approach to cervical cancer control. <i>Indian Journal of Medical Research</i> , 2009, 130, 241-6.	0.4	11
64	Interobserver Agreement in the Reporting of Cervical Biopsy Specimens Obtained From Women Screened by Visual Inspection With Acetic Acid and Hybrid Capture 2. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 509-515.	0.9	10
65	Evaluation of the national cervical cancer screening program in Morocco: achievements and challenges. <i>Journal of Medical Screening</i> , 2019, 26, 162-168.	1.1	10
66	Human papillomavirus vaccination: Good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1651-1660.	0.6	9
67	A pragmatic approach to tackle the rising burden of breast cancer through prevention & early detection in countries 'in transition'. <i>Indian Journal of Medical Research</i> , 2020, 152, 343.	0.4	9
68	Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: Results from a prospective cohort study. <i>International Journal of Cancer</i> , 2022, 151, 878-887.	2.3	9
69	A Prospective Randomized Trial to Compare Safety, Acceptability and Efficacy of Thermal Ablation and Cryotherapy in a Screen and Treat Setting. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1391-1398.	0.5	8
70	Telemedicine and Cancer Care in Low- and Middle-Income Countries During the SARS-CoV-2 Pandemic. <i>JCO Global Oncology</i> , 2021, 7, 1633-1638.	0.8	8
71	An international consensus on the essential and desirable criteria for an "organized" cancer screening programme. <i>BMC Medicine</i> , 2022, 20, 101.	2.3	8
72	Association of P16-RBSP3 inactivation with phosphorylated RB1 overexpression in basal-parabasal layers of normal cervix unchanged during CACX development. <i>Biochemical Journal</i> , 2016, 473, 3221-3236.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Patterns of care of breast cancer patients in Morocco – A study of variations in patient profile, tumour characteristics and standard of care over a decade. <i>Breast</i> , 2021, 59, 193-202.	0.9	7
74	Cervical screening by visual inspection with acetic acid (VIA) is well accepted by women—results from a community-based study in rural India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2006, 7, 604-8.	0.5	7
75	Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. <i>International Journal of Cancer</i> , 2020, 147, 1855-1863.	2.3	6
76	Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. <i>International Journal of Cancer</i> , 2020, 147, 9-13.	2.3	6
77	Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study. <i>PLoS ONE</i> , 2020, 15, e0244242.	1.1	6
78	Delivering colorectal cancer screening integrated with primary health care services in Morocco: Lessons learned from a demonstration project. <i>Cancer</i> , 2022, 128, 1219-1229.	2.0	6
79	HPV vaccination in women over 25 years of age: Asian Cervical Cancer Prevention Advisory Board recommendations. <i>Journal of Obstetrics and Gynaecology Research</i> , 2009, 35, 712-716.	0.6	5
80	Role of integrative medicine in the continuum of care of breast cancer patients in the Indian context. <i>Cancer Causes and Control</i> , 2021, 32, 429-440.	0.8	5
81	Efficacy, acceptability and safety of ablative versus excisional procedure in the treatment of histologically confirmed <sc>CIN2</sc>/3: A systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2023, 130, 153-161.	1.1	5
82	Human Papillomavirus (HPV) Testing for Secondary Prevention of Cervical Cancer. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 201-212.	0.3	4
83	The use of thermal ablation in diverse cervical cancer –screen and treat–service platforms in Zambia. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 157, 85-89.	1.0	4
84	Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol. <i>BMJ Open</i> , 2020, 10, e037955.	0.8	4
85	Mobile Screening Unit (MSU) for the Implementation of the –Screen and Treat–™ Programme for Cervical Cancer Prevention In Pune, India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 413-418.	0.5	3
86	Healthcare Systems Need to be Organized to Fight two Pandemics Simultaneously. <i>Asian Pacific Journal of Cancer Care</i> , 2020, 5, 1-3.	0.0	3
87	Concordance between hybrid capture 2 results performed on cervical samples obtained before and immediately after visual inspection with acetic Acid test. <i>International Journal of Preventive Medicine</i> , 2014, 5, 191-5.	0.2	3
88	Europe's path to eliminating cervical cancer as a public health problem. <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100276.	3.0	2
89	Alteration of Human Papillomavirus Type 16 Genetic and Epigenetic Profiles in Cervical Cancer Patients Is Indicative of Poor Disease Prognosis: A Cohort Analysis. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 750-757.	1.2	1
90	Screening for Epithelial Ovarian Cancer: An Updated Review. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 1.	0.1	1

#	ARTICLE	IF	CITATIONS
91	Training Future Leaders: Experience from China-ASEAN Cancer Control Training Program. Journal of Cancer Education, 2019, 34, 1067-1073.	0.6	1
92	Human papillomavirus (HPV) DNA and mRNA primary cervical cancer screening: Evaluation and triaging options for HPV-positive women. Journal of Medical Screening, 2019, 26, 212-218.	1.1	1
93	Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis. BMC Women's Health, 2020, 20, 253.	0.8	1
94	Pulling the investment levers on implementation research in oncology. Lancet Oncology, The, 2022, 23, 451-452.	5.1	1
95	Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India. International Journal of Cancer, 2023, 152, 249-258.	2.3	1
96	Extra-Genital Bowen's Disease on Abdomen Co-existing with Vulvar Intraepithelial Neoplasia. Journal of Obstetrics and Gynecology of India, 2016, 66, 199-201.	0.3	0
97	Author's reply to: Implementation and organization of cancer screening in France. International Journal of Cancer, 2018, 143, 3035-3035.	2.3	0
98	Author's reply to: Cancer screening policy in Hungary. International Journal of Cancer, 2018, 143, 1005-1005.	2.3	0
99	Response to the author: invitation to cancer screening: putting the car before the horse?. European Journal of Cancer Prevention, 2019, 28, 458-459.	0.6	0
100	Reply to: Chronic pain assessment and management during post-treatment follow up should be considered as a high value quality indicator for specialist breast cancer center. Breast, 2021, 60, 309.	0.9	0
101	Alternative analysis of the data from a HPV vaccine study in India – Authors' reply. Lancet Oncology, The, 2022, 23, e10.	5.1	0
102	Evolution of patterns of care for women with cervical cancer in Morocco over a decade. BMC Cancer, 2022, 22, 479.	1.1	0
103	Effectiveness of artificial intelligence-assisted decision-making to improve vulnerable women's participation in cervical cancer screening in France: a cluster randomized controlled trial (AppDate-You) (Preprint). JMIR Research Protocols, 0, , .	0.5	0